GSK'S CERVICAL CANCER VACCINE SHOWS PROMISE

In a late-stage trial, girls aged 10 to 14 who received GlaxoSmithKline's (GSK) vaccine to prevent infection with the virus that causes cervical cancer had immune responses twice as strong as women 15 to 25 years old given the vaccine.

The clinical trials were conducted in Europe and Russia, and involved 158 girls aged 10 to 14 and 458 women aged 15 to 25. Each of them received three doses of the vaccine over a period of six months.